Theoretically, our MS registry cohort might have included a subgroup of myelin oligodendrocyte glycoprotein immunoglobulin G (MOG-IgG) positive patients that are believed to have a more benign disease course. This evidence concerns the gene MOG and myeloid sarcoma.